Through analysis of the OS, RFS, PFS, and DSS of NCAPG in human cancer, NCAPG may be used for an unfavorable prognostic biomarker in patients with ACC, KIRC, KIRP, LGG, LIHC, LUAD, MESO, PAAD, PCPG, and SARC. This evidence concerns the gene NCAPG and adrenal cortex carcinoma.